ClinicalTrials.gg
Active, not recruitingNCT06332014Updated Feb 12, 2026

Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China

A Phase 4 interventional study of Prolia in Osteoporosis, sponsored by Amgen. Active, not recruiting at 16 sites in China. Open to male participants aged 30 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
30 Years to 90 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Enrollment
28th of 64
102 · median 90
Started
2024
with 4 others
Phase 4
19 of 64
5 open now
Primary completion
2027-01
later than 3 of 10 live
Registered
57th of 64
by date
Lead sponsor
22 of 64
Amgen

Among the 64 studies testing denosumab in Osteoporosis, this one is the 28th largest by enrollment, is one of 5 that started in 2024, is one of 19 in phase 4, reaches primary completion later than 3 of the 10 other live ones, and was the 57th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 30 Years to 90 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of Prolia on lumbar spine BMD at 12 months.

03

Conditions studied

  • Osteoporosis

Browse trials for

Keywords

  • Prolia
  • Denosumab
  • AMG 162
  • Osteoporosis
04

Who can participate

Ages eligible
30 Years to 90 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory Chinese men aged ≥ 30 years and ≤ 90 years old at the time of signing the .
  • Men at the time of screening will be required to have lumbar spine or total hip BMD T-score ≤ -2.5 or T-score ≤ -1.5 and a history of a fragility fracture.
  • Have to have at least two intact vertebrae at baseline (L1-L4).

Exclusion criteria

Exclusion Criteria:

  • Any condition that could affect bone metabolism such as Paget's disease of bone, osteomalacia including secondary causes of osteoporosis (subjects with low testosterone levels are allowed).
  • Hyper- or hypothyroidism; however, stable subjects, in the investigator's opinion, on thyroid hormone replacement therapy are allowed.
  • Participants with a history of any cancer (cured basal cell or squamous cell cancers are allowed).
  • Any condition that in the opinion of the investigator would not allow the subject to complete 1 year study and comply with the requirement of the study protocol.
  • Hypogonadism requiring testosterone replacement therapy unless on a stable dose for at least 12 months.
  • Administration of intravenous bisphosphonate, or fluoride (except for dental treatment) or strontium ranelate. Systemic : ≥ 7.5 mg prednisone equivalent per day for more than 14 days within 3 months before randomization. Any bone anabolic treatment within 1 year. Anabolic steroids or testosterone: any use within 6 months before randomization.
  • Oral bisphosphonates treatment.
  • Known to have tested positive for , virus, surface antigen, or cirrhosis of the liver.
  • Received any solid organ or bone marrow transplant or is on chronic for any reason.
  • Oral/dental conditions that would require an intervention including tooth extraction during the course of the study and invasive dental work (per local oral surgeon's assessment) planned in the next 12 months.
  • Any prior use of products containing denosumab.
  • Currently receiving treatment in another device or drug study, or less than 1 month since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
  • Vitamin D levels \< 20 ng/mL (subjects are allowed into the study after vitamin D levels are corrected and subjects re-screened).
  • Albumin-adjusted serum calcium levels \< 8.5 mg/dl or > 10.5 mg/dl.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Prolia

    Participants will receive Prolia every six months (Q6M)

    Drug: Prolia

Interventions

  • DrugProlia

    Partcipants will receive subcutaneous (SC) injections of Prolia Q6M.

    Also known as: Denosumab

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in bone mineral density (BMD) of lumbar spine at month 12

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Percent change from baseline in serum C-terminal telopeptide (CTx) at month 3, 6, 9, and 12

    Time frame: Baseline and Months 3, 6, 9, and 12

  2. Percent change from baseline in serum procollagen Type 1 N-Telopeptide (P1NP) at month 3, 6, 9, and 12

    Time frame: Baseline and Months 3, 6, 9, and 12

  3. Percent change from baseline in total hip and femoral neck BMD at month 6 and 12

    Time frame: Baseline and Months 6 and 12

  4. Percent change from baseline in lumbar spine BMD at month 6

    Time frame: Baseline and Month 6

  5. Number of participants with adverse events (AE)

    Time frame: Up to 12 Months

07

Study locations

16 sites
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jan 2027, 29 months after the start.

Of 65 phase 4 interventional studies under Osteoporosis, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 71. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2024
First posted
Mar 26, 2024
StartActual
Aug 6, 2024
Primary completionEst.
Jan 23, 2027
CompletionEst.
Jan 23, 2027
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06332014
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 26, 2024
Start date
Aug 6, 2024
Primary completion
Jan 23, 2027 (estimated)
Completion
Jan 23, 2027 (estimated)
Last update
Feb 12, 2026

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion